Scarica l'app Stockscreener
97.31
0.33%
-0.32
Dopo l'orario di chiusura:
97.29
-0.02
-0.02%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Incyte Corp Borsa (INCY) Ultime notizie
Michael James Morrissey Sells 4,323 Shares of Incyte (NASDAQ:INCY) Stock - MarketBeat
Incyte (INCY): Revisiting Valuation After a Strong Year-to-Date Share Price Rally - Yahoo Finance
First Chemotherapy-Free CD19/CD20 Lymphoma Regimen In Europe Might Change The Case For Investing In Incyte (INCY) - simplywall.st
EC Approves Label Expansion of INCY's Lymphoma Drug Minjuvi - Yahoo Finance
Incyte to Present at Upcoming Investor Conference - Barchart.com
EC approves Incyte’s Minjuvi combo for follicular lymphoma - Pharmaceutical Technology
Incyte wins European approval of Minjuvi in FL - The Pharma Letter
Incyte's Minjuvi Gets Second Nod From EC For R/R Follicular Lymphoma - Nasdaq
Incyte (INCY) Gains EU Approval for Minjuvi in Follicular Lympho - GuruFocus
Incyte (INCY) Gains European Approval for Minjuvi in New Cancer Treatment - GuruFocus
Minjuvi approved in EU for relapsed follicular lymphoma treatment By Investing.com - Investing.com South Africa
INCYTE wins European approval for Minjuvi cancer treatment - StreetInsider
(tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma - Business Wire
Is Incyte’s 2025 Surge Justified by Cash Flow Outlook and Oncology Pipeline Progress? - simplywall.st
Is Incyte Corp Gaining or Losing Market Support? - Sahm
Incyte Corp. stock outperforms competitors on strong trading day - MarketWatch
Palmetto Grain Brokerage - Palmetto Grain Brokerage
Is Incyte Stock Outperforming the Nasdaq? - Barchart.com
Incyte Lures New Top Lawyer With Hefty Equity Package Tied to Performance - MyChesCo
Bellevue Group AG Has $106.94 Million Holdings in Incyte Corporation $INCY - MarketBeat
Incyte Corporation (INCY) Announces Retirement of Board Member H - GuruFocus
Incyte director Hervé Hoppenot retires from board effective immediately By Investing.com - Investing.com Canada
Incyte director Hervé Hoppenot retires from board effective immediately - Investing.com
Hervé Hoppenot resigns from Incyte’s board of directors - Investing.com
Incyte Announces Change to its Board of Directors - Barchart.com
WINTON GROUP Ltd Makes New Investment in Incyte Corporation $INCY - MarketBeat
Ieq Capital LLC Has $27.52 Million Position in Incyte Corporation $INCY - MarketBeat
Incyte’s Blood Cancer Drug Shows Promise, But Hurdles Remain - Finimize
Incyte Corporation $INCY Shares Acquired by Investment Management Corp of Ontario - MarketBeat
Incyte stock rating reiterated by RBC, firm notes ’989 program viability - Investing.com
Jump Financial LLC Purchases 70,768 Shares of Incyte Corporation $INCY - MarketBeat
California Public Employees Retirement System Sells 122,593 Shares of Incyte Corporation $INCY - MarketBeat
Amundi Purchases 101,220 Shares of Incyte Corporation $INCY - MarketBeat
Incyte releases data that shows promise in treating rare blood disease - Delaware Business Now
Sun Pharma Claims New Pill Distinct From Incyte's Hit Drug - Law360
Incyte (NASDAQ:INCY) Upgraded at Mizuho - MarketBeat
Incyte Presents Updated Positive Data at ASH 2025 Reinforcing the Potential of INCA033989, its First-in-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Essential Thrombocythemia - BioSpace
Incyte stock holds Market Perform rating at Citizens on CALR therapy lead - Investing.com
Is Incyte Still Attractive After Its Strong 2025 Rally and DCF Valuation Gap? - Yahoo Finance
Is Incyte (INCY) Quietly Reframing Its R&D Story With Breakthrough Status And Legal Firepower? - Yahoo Finance
Incyte (INCY) Reports Promising Phase 1 Results for INCA033989 i - GuruFocus
Incyte’s experimental drug shows strong response in blood disorder By Investing.com - Investing.com Canada
Incyte’s experimental drug shows strong response in blood disorder - Investing.com
Incyte presents data showing 90% response rate for blood cancer drug - StreetInsider
Incyte Corp. stock outperforms competitors despite losses on the day - MarketWatch
Institution Moves: Why Incyte Corporation ICY stock stays undervaluedWatch List & Short-Term Trading Alerts - BỘ NỘI VỤ
Incyte (NASDAQ:INCY) Trading Down 6.6%Should You Sell? - MarketBeat
Incyte (INCY) Maintained as Equal-Weight by Morgan Stanley with Raised Price Target | INCY Stock News - GuruFocus
INCY: Wells Fargo Raises Price Target to $116 | INCY Stock News - GuruFocus
Incyte gains FDA Breakthrough designation for its candidate against essential thrombocythemia - marketscreener.com
Incyte's Rare Blood Cancer Therapy Gets FDA's Breakthrough Status - Yahoo Finance
Incyte (INCY) Stock Receives Upgraded Rating and Price Target fr - GuruFocus
What's Going On With Incyte Stock Monday?Incyte (NASDAQ:INCY) - Benzinga
Incyte's New Therapy Shows Signs Of 'Disease-Modifying' Potential In Rare Blood Cancer - Sahm
Leerink Partners Adjusts Incyte Price Target to $128 From $103, Maintains Outperform Rating - marketscreener.com
Incyte stock price target raised to $128 by Leerink on mCALR data - Investing.com
Incyte Corporation $INCY Shares Purchased by American Century Companies Inc. - MarketBeat
Incyte Says Rare Blood Cancer Therapy Receives FDA Breakthrough Designation - marketscreener.com
Incyte Names Veteran Biopharma Attorney as New General Counsel - MyChesCo
Wells Fargo Adjusts Price Target on Incyte to $116 From $97, Maintains Overweight Rating - marketscreener.com
Mizuho upgrades Incyte stock rating to Outperform on promising ASH data - Investing.com
Incyte stock price target raised by BofA to $118 on promising blood disorder data - Investing.com
Mizuho Upgrades Incyte to Outperform From Neutral, Adjusts Price Target to $121 From $90 - marketscreener.com
First Trust Advisors LP Sells 12,101 Shares of Incyte Corporation $INCY - MarketBeat
Transcript : Incyte CorporationSpecial Call - marketscreener.com
Incyte (INCY) Secures FDA Breakthrough Therapy Designation for I - GuruFocus
Incyte (INCY) Reveals Promising Phase 1 Results for INCA033989 i - GuruFocus
Incyte (INCY) Receives FDA Breakthrough Therapy Designation for INCA033989 - GuruFocus
Incyte’s First-in-Class mutCALR-Targeted Monoclonal Antibody, INCA033989, Granted Breakthrough Therapy Designation by U.S. FDA - Business Wire
18,946 Shares in Incyte Corporation $INCY Bought by 1832 Asset Management L.P. - MarketBeat
Incyte Announces New Positive Data for INCA033989, its First-In-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Myelofibrosis Presented at ASH 2025 - Yahoo Finance
0.66%
0.31%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):